SkyePharma DepoCyt To Be Launched In May, Solid Tumor NDA Planned
Executive Summary
SkyePharma is considering resubmitting an NDA for DepoCyt in the treatment of neoplastic meningitis resulting from solid tumors now that the sustained-release intrathecal cytarabine product has cleared FDA for treatment of lymphomatous meningitis.